Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pegg

Showing results (1171-1180 of 1,192) with videos related to

Pageof 120
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant gliomaJennifer A Quinn, James Pluda, M Eileen Dolan, et al.
Nature|June 12, 2009
Flipping of alkylated DNA damage bridges base and nucleotide excision repairJulie L Tubbs, Vitaly Latypov, Sreenivas Kanugula, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant gliomaJennifer A Quinn, Annick Desjardins, Jon Weingart, et al.
Bioorganic & Medicinal Chemistry Letters|July 9, 1999
Thrombin inhibitors based on [5,5] trans-fused indane lactamsM Pass, S Abu-Rabie, A Baxter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant gliomaH S Friedman, J Pluda, J A Quinn, et al.
Nature Structural & Molecular Biology|January 18, 2011
Structural basis of substrate discrimination and integrin binding by autotaxinJens Hausmann, Satwik Kamtekar, Evangelos Christodoulou, et al.
American Journal of Medical Genetics. Part A|December 18, 2025
Genetic and Phenotypic Features of the Five Known Polyaminopathies: A Critical Narrative ReviewElizabeth A VanSickle, Sara M Sarasua, Tracy Lowe, et al.
Journal of Medicinal Chemistry|October 11, 2011
Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancerDaniel P Sutherlin, Linda Bao, Megan Berry, et al.
Bioorganic & Medicinal Chemistry Letters|June 8, 2012
Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelfDaniel P Sutherlin, Stewart Baker, Angelina Bisconte, et al.
Bioorganic & Medicinal Chemistry Letters|June 13, 2009
Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitorsMartin E Swarbrick, Paul J Beswick, Robert J Gleave, et al.
Pageof 120

Showing results (1171-1180 of 1,192) with videos related to

Sort By:
Pageof 120
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant gliomaJennifer A Quinn, James Pluda, M Eileen Dolan, et al.
Nature|June 12, 2009
Flipping of alkylated DNA damage bridges base and nucleotide excision repairJulie L Tubbs, Vitaly Latypov, Sreenivas Kanugula, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant gliomaJennifer A Quinn, Annick Desjardins, Jon Weingart, et al.
Bioorganic & Medicinal Chemistry Letters|July 9, 1999
Thrombin inhibitors based on [5,5] trans-fused indane lactamsM Pass, S Abu-Rabie, A Baxter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant gliomaH S Friedman, J Pluda, J A Quinn, et al.
Nature Structural & Molecular Biology|January 18, 2011
Structural basis of substrate discrimination and integrin binding by autotaxinJens Hausmann, Satwik Kamtekar, Evangelos Christodoulou, et al.
American Journal of Medical Genetics. Part A|December 18, 2025
Genetic and Phenotypic Features of the Five Known Polyaminopathies: A Critical Narrative ReviewElizabeth A VanSickle, Sara M Sarasua, Tracy Lowe, et al.
Journal of Medicinal Chemistry|October 11, 2011
Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancerDaniel P Sutherlin, Linda Bao, Megan Berry, et al.
Bioorganic & Medicinal Chemistry Letters|June 8, 2012
Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelfDaniel P Sutherlin, Stewart Baker, Angelina Bisconte, et al.
Bioorganic & Medicinal Chemistry Letters|June 13, 2009
Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitorsMartin E Swarbrick, Paul J Beswick, Robert J Gleave, et al.
Pageof 120